Science Deep Dive Bio-Performance
Testosterone is not the cartoon molecule of gym culture, it is a precisely regulated signalling hormone whose decline is measurable, whose mechanisms are mapped, and whose consequences reach from body composition to mortality.
22 min read
Bio-Performance

The Complete Science of Testosterone: What 55 Studies Actually Show

Testosterone is not the cartoon molecule of gym culture, it is a precisely regulated signalling hormone whose decline is measurable, whose mechanisms are mapped, and whose consequences reach from body composition to mortality.

Mechanism
Controlled Human Data
Interpretation
Peer-reviewed evidence · Editorial synthesis
— What the Research Actually Found —

Four headline statistics drawn from gold-tier evidence, each independently verified, each telling a different part of the same story.

Secular Decline ~17 % decline

Population-level testosterone in American men has declined approximately 17% over two decades, independent of aging, a shift not fully explained by obesity, smoking, or any single factor.[1]

Large Cohort
[1]
Sleep Architecture 10–15 % reduction

Restricting sleep to five hours per night for just one week reduced daytime testosterone by 10–15% in healthy young men, a decline comparable in magnitude to roughly a decade of normal age-related loss.[34]

RCT
[34]
Dose-Response +7.9 kg lean mass

In a GnRH-suppression trial isolating testosterone as the sole variable, fat-free mass increased by 7.9 kg at the highest dose over 20 weeks, causal, dose-dependent, and exercise-independent.[17]

RCT
[17]
Mortality Signal 35 % ↑ risk

Low endogenous testosterone is associated with a 35% increase in all-cause mortality across 12 prospective cohorts and 16,184 men, though Mendelian randomization studies have not confirmed a causal relationship.[24]

Meta-Analysis
[24]
47 Peer-reviewed sources
Evidence Signal

Controlled human data, large-scale RCTs, and population cohorts converge on the same conclusion: testosterone is a systemic regulator whose status predicts outcomes across every major organ system.

Study Mix
RCT
14
Meta
8
Cohort
12
Review
13
Editorial Judgment

The evidence base for testosterone's biology is unusually strong, anchored by dose-response RCTs that establish causation, not just association, for the anabolic and metabolic effects.

The molecule was isolated in 1935 in an Amsterdam laboratory, extracted from bull testes, crystallized, and named for what it was: the substance from the testes.[3] Within months, Adolf Butenandt and Leopold Ruzicka had independently synthesized it, a feat that earned both the 1939 Nobel Prize in Chemistry. Nearly a century later, testosterone remains the most discussed hormone in human performance, and the most misunderstood. The popular conversation splits neatly into two camps: those who treat it as the master switch for masculinity and those who dismiss the entire topic as pharmaceutical marketing. Neither camp has read the evidence.

The evidence is substantial. Fifty-five peer-reviewed sources, spanning dose-response RCTs, the largest cardiovascular safety trial ever conducted on a hormone, meta-analyses covering more than 16,000 men, and controlled sleep-restriction experiments, describe a molecule whose influence is simultaneously more precise and more far-reaching than either camp acknowledges.[17][19][24][34] Testosterone does not simply "make you strong." It regulates a signalling cascade that touches muscle protein synthesis, glucose metabolism, bone mineral turnover, dopaminergic motivation circuits, and erythropoiesis. When that cascade is disrupted, by sleep restriction, chronic stress, visceral adiposity, or endocrine-disrupting chemicals, the consequences are not confined to the gym. They show up in metabolic panels, mood inventories, cognitive screens, and mortality tables.

That matters because the secular decline is real and accelerating. Travison's Massachusetts Male Aging Study found that age-matched American men in 2003 had testosterone levels approximately 17% lower than men the same age in 1987, a population-level shift not fully explained by changes in obesity or smoking.[1] The decline is not limited to older men. Lokeshwar's 2021 analysis confirmed the same secular decline in adolescent and young adult males aged 15 to 39.[5]

Editorial pause
The testosterone conversation is not about gym culture. It is about a systemic regulatory signal that is measurably declining across the population, at every age.

Nobel Prize, 1939, Ruzicka and Butenandt shared the Chemistry prize for synthesizing testosterone. Butenandt was forced by the Nazi government to decline. He accepted retroactively in 1949.

The question this article answers is not "How do I raise my testosterone?" That framing assumes the problem is one of supplementation, which is exactly the misunderstanding that leads people astray. The real question is architectural: how does the hypothalamic-pituitary-gonadal axis actually regulate testosterone production, what disrupts it, and what does the disruption cost?

Understanding the architecture changes the intervention logic. If the HPG axis is a feedback-controlled signalling system, which it is, then the first question is not "What should I take?" but "What is suppressing the signal?" Sleep debt, visceral fat, chronic cortisol elevation, and micronutrient deficiency all suppress the signal upstream.[34][32][39] Removing the suppression is not the same as adding the molecule. The distinction matters clinically: the Endocrine Society's 2018 guidelines require both low levels and symptoms before diagnosis, precisely because the number alone does not tell you where the system broke.[40]

The prevalence numbers suggest the system is breaking often. Mulligan's HIM study found that 38.7% of men over 45 presenting to primary care had total testosterone below 300 ng/dL, the threshold most guidelines use for biochemical hypogonadism.[2] That is not a niche clinical population. That is more than a third of middle-aged men walking into a doctor's office.

Editorial pause
The real question is not how to add testosterone but how to stop suppressing the axis that produces it.

This article maps the full arc: mechanism, evidence, stakes, and protocol. The Mechanism block traces the HPG axis from hypothalamic pulse generator to androgen receptor activation. The Evidence block ranks the five strongest studies in the field, including the only RCT that has ever isolated testosterone as a single causal variable by suppressing endogenous production to near-zero.[17] The Stakes block quantifies what breaks when the system fails: metabolic syndrome, cognitive erosion, physical deterioration, and a mortality signal that persists across a dozen cohorts.[24][26][28] The Protocol block translates the mechanism into four evidence-informed interventions, each targeting a specific upstream suppressor.

The voice throughout is editorial, not encyclopedic. Where the evidence is strong, the language is direct. Where it is contested, and several findings are genuinely contested, including the causal status of the mortality association, the hedging is explicit and sourced. The goal is not to sell testosterone. The goal is to show what the science actually says, with enough precision that the reader can make decisions the research supports.

Editorial pause (Section verdict)
Testosterone science is not a debate between believers and skeptics. It is a mapped system with quantified failure modes, and the evidence is strong enough to act on.
The Mechanism

The HPG Axis: How Testosterone Is Made, Moved, and Used

The system starts with a pulse. Every 90 to 120 minutes, a cluster of neurons in the hypothalamus releases gonadotropin-releasing hormone (GnRH) in a precisely timed burst.[6] The pulsatility is not incidental, it is the signal itself. Continuous GnRH administration paradoxically suppresses the downstream cascade, which is why GnRH agonists are used clinically to shut testosterone production down. The pulse frequency encodes the instruction. Change the frequency and you change what the pituitary does with the message.

The anterior pituitary translates each GnRH pulse into a surge of luteinising hormone (LH), which travels through the bloodstream to the testes.[6][10] LH has a half-life of roughly 60 minutes, long enough to reach its target, short enough to preserve the pulsatile signal. At the testes, LH binds to receptors on Leydig cells, triggering a cAMP-PKA cascade that initiates steroidogenesis.[6] The rate-limiting step is the conversion of cholesterol to pregnenolone by the enzyme CYP11A1, the molecular bottleneck through which all testosterone must pass.[7]

Four enzymes complete the synthesis: CYP11A1, HSD3B, CYP17A1, and HSD17B3.[7] The last, HSD17B3, converts androstenedione into testosterone. Deficiency of this enzyme in animal models produces striking changes in extragonadal androgen metabolism, confirming that the testicular pathway is not the body's only route to androgens, but it is overwhelmingly the dominant one: roughly 95% of circulating testosterone in men is Leydig-cell derived.[6]

Editorial pause
The HPG axis is not a thermostat. It is a pulse-coded signal chain, and the code matters as much as the volume.

Once synthesized, testosterone enters the bloodstream and immediately encounters a distribution problem. Goldman's landmark reappraisal of testosterone binding found that approximately 44% binds to sex hormone-binding globulin (SHBG) and becomes functionally inactive.[8] Another 50% binds loosely to albumin, bioavailable but not immediately active. Only about 2% circulates as free testosterone, the fraction that can walk directly into a cell and bind an androgen receptor.[8][9]

That 2% figure reshapes how you think about testosterone levels. A man with high total testosterone but elevated SHBG may have less biologically active hormone than a man with moderate total levels and low SHBG. Narinx's 2022 work complicated this further: SHBG is not merely a passive carrier protein. It has its own cellular receptor and may exert direct signalling effects independent of the testosterone it carries.[9] The clinical implication is that total testosterone alone is an incomplete measurement, which is why the Endocrine Society recommends calculating free or bioavailable testosterone when SHBG is suspected to be abnormal.[40]

The diurnal rhythm adds another layer. Brambilla's 2009 study established that testosterone peaks between 7 and 9 AM and drops 20–25% by late afternoon in men under 40.[13] The clinical guideline, draw blood in the morning, exists because afternoon sampling systematically underestimates a man's peak production. That detail matters because population studies that don't control for sampling time introduce noise that can obscure real differences.

Editorial pause
Only about 2% of circulating testosterone is immediately active, which means the binding system is as important as the production system.

At the target tissue, the molecule's work divides into two modes. The classical pathway is genomic: testosterone binds the androgen receptor (AR), the complex translocates to the nucleus, and gene expression changes.[12][14] In skeletal muscle, Bhasin's 2025 review identified the primary anabolic cascade: AR activation triggers a β-catenin → TCF4 → follistatin pathway that promotes myogenesis, the creation of new muscle fibers.[10] Critically, conversion to dihydrotestosterone (DHT) via 5α-reductase is not required for the muscle-building effect, which explains why 5α-reductase inhibitors (finasteride, dutasteride) do not cause significant muscle loss.

The second mode is non-genomic signalling: rapid membrane-initiated events that occur within seconds, far too fast for gene transcription.[12] In the brain, androgen receptors are concentrated in the ventral tegmental area, nucleus accumbens, and prefrontal cortex, the architecture of motivation, reward, and executive function.[11] Testosterone modulates dopaminergic signalling in these circuits, which is why low testosterone correlates not only with depressed mood but with a specific quality of motivational flatness that patients describe as losing their drive.[30]

A secondary pathway runs through aromatase, the enzyme that converts testosterone to estradiol (E2). Approximately 80% of male estradiol is aromatized from testosterone in peripheral tissues, predominantly adipose and brain.[8] This conversion is not a loss. In bone, estradiol is the primary driver of mineral density. In the hypothalamus, estradiol participates in the negative feedback loop that regulates GnRH pulsatility. The aromatase pathway is also why visceral fat creates a vicious cycle: more fat tissue means more aromatase, more estradiol, stronger negative feedback, and lower testosterone production upstream.[32]

Editorial pause
Testosterone acts through two distinct modes, slow genomic remodelling and fast neural signalling, which is why its effects span from muscle mass to motivation.

That binding arithmetic has a practical consequence: anything that raises SHBG, aging, liver disease, hyperthyroidism, certain medications, reduces bioavailable testosterone without changing the total number on a lab report. Conversely, anything that lowers SHBG, obesity, insulin resistance, hypothyroidism, inflates the bioavailable fraction temporarily, masking a system that is already under strain.[8][9] The Endocrine Society's position statement on testosterone measurement warns that standard immunoassays have poor accuracy at low concentrations and recommends liquid chromatography-mass spectrometry (LC-MS/MS) as the gold standard.[52]

The dual-hormone hypothesis adds the final layer. Mehta and Josephs demonstrated that testosterone's effect on dominance behaviour depends on cortisol: high testosterone paired with low cortisol produces dominant, status-seeking behaviour, while high testosterone paired with high cortisol produces no behavioural effect at all.[43] The cortisol-testosterone interaction is not merely behavioural. Chronic cortisol elevation suppresses GnRH pulsatility directly, creating a mechanistic link between sustained stress and reduced testosterone that operates upstream of everything else in the cascade.[6][10]

Editorial pause
The HPG axis is a signal-quality problem, and cortisol, sleep debt, and visceral fat are the three loudest sources of noise.

"The axis does not need stimulation. It needs the noise removed."

— Editorial synthesis of HPG axis research
~2%

of circulating testosterone is immediately bioactive as free hormone, the rest is bound to SHBG or albumin, functionally sequestered from target tissues

Goldman et al. (2017) · Endocrine Reviews · Population reappraisal of testosterone binding
The 5 Strongest Studies on Testosterone Science

Scored on a 100-point rubric across six criteria, design, sample, rigour, causality, replication, and field influence. The flagship study ranks first not for scale but for causal precision.

5

#1
87/100
/100
Bhasin et al. (2001), Testosterone Dose-Response Relationships in Healthy Young Men
+7.9 kg

RCT GnRH-Suppression Dose-Response
Design28/30 Sample10/20 Rigour14/15 Causality15/15 Replication10/10 Citations10/10
Supporting evidence · Rank 2–5
Largest cardiovascular safety RCT in testosterone medicine
84/100
/100
Lincoff et al. (2023), Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE)
Lincoff et al.
0.96 **Stat unit:** HR (MACE)
Major adverse cardiac events occurred in 7.0% of the testosterone group versus 7.3% of placebo (HR 0.96, 95% CI 0.78–1.17; P < 0.001 for non-inferiority). Atrial fibrillation was higher in the testosterone group (3.5% vs. 2.4%).
TRT does not increase heart attack or stroke risk in hypogonadal men with pre-existing cardiovascular risk, definitively resolving a decade-long controversy sparked by the 2010 Basaria adverse-event signal.[50]
Most comprehensive multi-outcome efficacy RCT program
79/100
/100
Snyder et al. (2016), Testosterone Trials (TTrials): Effects of Testosterone Treatment in Older Men
Snyder et al.
P < 0.001 **Stat unit:** sexual function improvement
In 788 hypogonadal men (mean age 72), testosterone significantly improved sexual activity, desire, and walking distance versus placebo. Anemia correction rate: 58.3% versus 22.2%. No cognitive benefit in the dedicated cognitive sub-trial.[18][21]
TRT in older hypogonadal men produces clinically meaningful benefits for sexual function and physical performance, corrects unexplained anemia, but does not improve cognition.
Cleanest causal evidence for a modifiable behavioral regulator
72/100
/100
Leproult & Van Cauter (2011), Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy Men
Leproult & Van Cauter
10–15 **Stat unit:** % reduction in daytime testosterone
One week of sleeping five hours per night reduced daytime testosterone by 10–15% in 10 healthy young men under controlled laboratory conditions. The decline was especially pronounced between 2 PM and 10 PM.[34]
Sleep curtailment causally suppresses testosterone on a clinically meaningful timescale in healthy young men, a decline comparable to roughly a decade of normal age-related loss.
Largest meta-analytic mortality signal for endogenous testosterone
68/100
/100
Araujo et al. (2011), Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis
Araujo et al.
1.35 **Stat unit:** RR (all-cause mortality)
Across 12 prospective cohort studies and 16,184 subjects (mean follow-up 9.7 years), men in the lowest testosterone tertile had a 35% higher relative risk of all-cause mortality (RR 1.35, 95% CI 1.13–1.62).[24] Shores independently found an 88% higher mortality risk in a veterans cohort.[31]
Low endogenous testosterone is robustly associated with excess mortality across diverse populations, but observational design means the association may partly reflect reverse causation or residual confounding. Mendelian randomization analyses have not confirmed a causal link.
Editorial judgment

The four domains are not independent. The metabolic cascade drives the physical deterioration. The mood erosion compounds the motivational deficit that makes lifestyle intervention harder. The mortality signal, real or confounded, sits downstream of all three. The system fails as a system, not as isolated components, which is why single-variable interventions (testosterone gel without addressing sleep, or exercise without addressing cortisol) frequently underperform expectations.

The environmental dimension adds urgency. Population-level testosterone has been declining for decades, and the decline is not fully explained by rising obesity rates.[1][4] Endocrine-disrupting chemicals, particularly phthalates, show dose-dependent associations with lower testosterone in population-representative NHANES data.[33] Lokeshwar's finding that the decline extends to adolescents and young adults means this is not an aging phenomenon.[5] It is an environmental exposure story overlaid on an aging story, and the two are multiplicative.

Editorial pause
The stakes are not confined to individual men. They are population-level, multi-system, and accelerating, driven by environmental exposures that affect men before they are old enough to notice.
What Breaks When Testosterone Breaks

Four Systems, One Cascade

Low testosterone is not a single-symptom condition. It is a systemic disruption that shows up differently depending on which downstream pathway fails first.

System 01
Metabolic Collapse
Low testosterone increases visceral adiposity, which increases aromatase activity, which converts more testosterone to estradiol, which strengthens negative feedback and further suppresses production. The result is a self-reinforcing cycle that Rao's 2013 Nature Reviews synthesis describes as bidirectional: low testosterone promotes insulin resistance, insulin resistance promotes obesity, and obesity promotes lower testosterone.[32] Kupelian found that 43–57% of men with type 2 diabetes have biochemical hypogonadism.[27]
57%
What it feels like · Central weight gain unresponsive to exercise; rising fasting glucose; expanding waist despite unchanged diet
System 02
Cognitive and Mood Erosion
Testosterone modulates dopaminergic signalling in the mesocorticolimbic system, the neural architecture of motivation, reward, and executive function.[11] Zitzmann's review found that 35–50% of hypogonadal men report depressive symptoms.[30] Marriott's UK Biobank analysis (N=159,411) found an 11% increase in dementia risk per standard deviation decrease in baseline testosterone.[28] The mood signal is real; the cognitive signal is observational and unconfirmed by treatment trials.
50%
What it feels like · Brain fog; motivational flatness; emotional blunting; the sense of having lost a competitive edge
System 03
Physical Deterioration
The anabolic cascade, AR → β-catenin → follistatin → myogenesis, requires testosterone as input.[10] Without it, type II fast-twitch muscle fibers are preferentially lost, grip strength declines, recovery slows, and sarcopenia accelerates. TRT in older men has been shown to increase lean body mass, walking distance, and volumetric bone density, but the TRAVERSE fracture substudy found it did not reduce, and may have increased, fracture incidence.[18][20]
What it feels like · Muscle loss despite training; slower recovery; visible fat redistribution; declining physical performance
System 04
Systemic Longevity Risk
Araujo's meta-analysis found a 35% increased all-cause mortality risk in men with low endogenous testosterone.[24] Shores found an 88% higher mortality risk in a veterans cohort over 8 years.[31] The association is robust across diverse populations, but Mendelian randomization studies, which use genetic variation to approximate randomised exposure, have not confirmed a causal relationship. Low testosterone may be a marker of poor health rather than its independent cause. The clinical implication: monitor and address the upstream drivers, do not treat the number alone.
35%
What it feels like · Low energy as baseline; elevated cardiovascular markers; the subjective sense of accelerated aging
1 / 4

A note on exercise: Smith's 2022 meta-analysis found that exercise training has a negligible effect on resting testosterone in healthy inactive men (g ≈ 0.1).[35] The exception is clinically meaningful: Hsiao's 2024 meta-analysis found a moderate effect of aerobic exercise on testosterone in obese men and those with type 2 diabetes (g = 0.565, P < 0.001).[36] The mechanism is not a direct testosterone boost. It is fat loss reducing aromatase activity and insulin resistance, which in turn reduces HPG suppression. Exercise works through body composition, not around it.

The protocol is evidence-informed, not evidence-mandated. No RCT has tested all four steps simultaneously. The logic is mechanistic: each step targets a documented suppressor with a plausible and, in most cases, demonstrated upstream effect. Where the evidence is strongest (sleep, body composition), the confidence is high. Where it is weaker (micronutrient correction in non-deficient populations), the recommendation is conditional: test first, then act.

Editorial pause
The protocol is not four unrelated tips. It is a coordinated de-suppression strategy, each step removing a specific source of noise from the same axis.
Translation Layer · What Changes Tomorrow Morning

A Signal-Quality Protocol for Testosterone Optimisation

Every step targets a specific upstream suppressor of the HPG axis. The operating principle: the axis does not need stimulation, it needs the noise removed.

01
Nightly
Sleep Architecture
Rule
Protect 7–9 hours of uninterrupted sleep; anchor a consistent wake time.
15%
Why
Leproult's controlled study showed that one week of 5-hour nights reduced daytime testosterone by 10–15%. Testosterone and growth hormone both peak during slow-wave sleep, curtailing sleep curtails the production window.[34][53]
Common mistake
Treating sleep debt with weekend catch-up. The hormonal suppression from chronic short sleep is not reversed within two recovery nights.
02
Ongoing
Body Composition
Rule
Target visceral fat reduction; 10% body weight loss can raise testosterone by 14–37%.
Why
Aromatase in adipose tissue converts testosterone to estradiol, strengthening negative feedback on the HPG axis. Corona's meta-analysis confirmed that weight loss reverts obesity-associated hypogonadotropic hypogonadism.[39][32]
Common mistake
Aggressive caloric restriction without protein adequacy, severe deficit suppresses testosterone independently of fat loss, creating a paradox where the intervention worsens the signal.
03
Daily
Stress Load
Rule
Reduce chronic cortisol burden through structured recovery periods.
Why
The dual-hormone model shows high cortisol blocks testosterone's behavioural effects even when testosterone is adequate.[43] Chronic cortisol elevation suppresses GnRH pulsatility directly, reducing production upstream of everything else.[6][10]
Common mistake
Adding training volume to "boost testosterone" when cortisol is already elevated, the net result is further HPG suppression, not stimulation.
04
As needed
Nutritional Substrates
Rule
Test for zinc and vitamin D deficiency before supplementing; correct deficiencies, do not megadose.
Why
Prasad's study found that zinc supplementation in marginally deficient elderly men nearly doubled testosterone over six months (8.3 → 16 nmol/L).[38] But this effect is corrective, not additive, replete men see near-zero benefit. Most "testosterone booster" supplements lack robust evidence in non-deficient populations.
Common mistake
Taking high-dose zinc or vitamin D without testing, excess zinc depletes copper; excess vitamin D is hepatotoxic. Supplementation without confirmed deficiency is expense without return.
1 / 4

The four steps share a common logic: each removes a specific suppressor from the HPG axis, sleep debt, visceral aromatase, cortisol-driven GnRH suppression, and enzymatic cofactor deficiency. The protocol is upstream-first by design.

and the noise is sleep debt, visceral fat, chronic stress, and nutritional deficiency.
The Verdict
01
Claim
The Signalling System
Testosterone is produced by a pulsatile, feedback-controlled HPG axis whose output depends on signal quality at every node. The anabolic effects are causal and dose-dependent, established by the only RCT that has ever isolated testosterone as a single variable.[17]
02
Consequence
The Failure Cascade
When the axis is chronically suppressed, by sleep debt, visceral fat, cortisol, or deficiency, the downstream effects cascade through metabolism, mood, physical performance, and potentially mortality. The system fails as a system, not as isolated symptoms.
03
Lever
The Upstream Protocol
The highest-leverage interventions target the four modifiable suppressors: sleep architecture, body composition, stress load, and nutritional substrates. Removing the noise is more effective than adding the signal, because the axis is designed to self-correct when the inputs are clean.[34][40][44][38]
High (mechanism and safety) · Moderate (mood and metabolic) · Low (cognition and longevity)
High (mechanism and safety) · Moderate (mood and metabolic) · Low (cognition and longevity) Confidence
Causal evidence from GnRH-suppression RCTs · largest cardiovascular safety RCT (N=5,246) · replicated prospective cohort data · within-subject controlled sleep manipulation

References

0 sources cited — peer-reviewed sources

  1. 1Travison, T.G., Araujo, A.B., O'Donnell, A.B., Kupelian, V., & McKinlay, J.B. (2007). A population-level decline in serum testosterone levels in American men. Journal of Clinical Endocrinology & Metabolism, 92(1), 196–202. DOI: 10.1210/jc.2006-1375
  2. 2Mulligan, T., Frick, M.F., Zuraw, Q.C., Stemhagen, A., & McWhirter, C. (2006). Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International Journal of Clinical Practice, 60(7), 762–769. DOI: 10.1111/j.1742-1241.2006.00992.x
  3. 3Handelsman, D.J. (2019). Endocrine history: The history of discovery, synthesis and development of testosterone for clinical use. European Journal of Endocrinology, 180(6), R201–R212. DOI: 10.1530/EJE-19-0071
  4. 4Nieschlag, E., & Nieschlag, S. (2026). Understanding the secular decline in testosterone: mechanisms, consequences, and clinical perspectives. International Journal of Molecular Sciences, 27(2), 692. DOI: 10.3390/ijms27020692
  5. 5Lokeshwar, S.D., Patel, P., Fantus, R.J., et al. (2021). Decline in serum testosterone levels among adolescent and young adult men in the USA. European Urology Focus, 7(4), 886–889. DOI: 10.1016/j.euf.2020.02.006
  6. 6Garza-Culty, E.C., & Papadopoulos, V. (2023). How is the synthesis of testosterone regulated? In Andrology Society Textbook, Chapter 5. DOI: available via Andrology Society
  7. 7Baer, K.A., et al. (2022). New insights into testosterone biosynthesis: novel observations from HSD17B3 deficient mice. International Journal of Molecular Sciences, 23(24), 15554. DOI: 10.3390/ijms23241555
  8. 8Goldman, A.L., Bhasin, S., Wu, F.C.W., Krishna, M., Matsumoto, A.M., & Jasuja, R. (2017). A reappraisal of testosterone's binding in circulation: physiological and clinical implications. Endocrine Reviews, 38(4), 302–324. DOI: 10.1210/er.2017-00025
  9. 9Narinx, N., et al. (2022). Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology. Cellular and Molecular Life Sciences, 79(11), 543. DOI: 10.1007/s00018-022-04562-1
  10. 10Bhasin, S., Bhattacharya, R., & Storer, T.W. (2025). Mechanisms of testosterone's anabolic effects on muscle and function: controversies and new insights. Endocrine Reviews, 47(2), 280–300. DOI: 10.1210/endrev/bnaf041
  11. 11Behnke, B.J., & Rhee, J.M. (2018). Androgen regulation of the mesocorticolimbic system and executive function. Frontiers in Endocrinology, 9, 279. DOI: 10.3389/fendo.2018.00279
  12. 12Davey, R.A., & Grossmann, M. (2016). Androgen receptor structure, function and biology. Clinical Biochemist Reviews, 37(1), 3–15. PMID: 27057074
  13. 13Brambilla, D.J., Matsumoto, A.M., Araujo, A.B., & McKinlay, J.B. (2009). The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. Journal of Clinical Endocrinology & Metabolism, 94(3), 907–913. DOI: 10.1210/jc.2008-1902
  14. 14Mooradian, A.D., Morley, J.E., & Korenman, S.G. (1987). Biological actions of androgens. Endocrine Reviews, 8(1), 1–28. DOI: 10.1210/edrv-8-1-1
  15. 15Phoenix, C.H., Goy, R.W., Gerall, A.A., & Young, W.C. (1959). Organizing action of prenatally administered testosterone propionate on the tissues mediating mating behavior in the female guinea pig. Endocrinology, 65, 369–382. DOI: 10.1210/endo-65-3-369
  16. 16Bhasin, S., Storer, T.W., Berman, N., et al. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine, 335(1), 1–7. DOI: 10.1056/NEJM199607043350101
  17. 17Bhasin, S., Woodhouse, L., Casaburi, R., et al. (2001). Testosterone dose-response relationships in healthy young men. American Journal of Physiology, Endocrinology and Metabolism, 281(6), E1172–E1181. DOI: 10.1152/ajpendo.2001.281.6.E1172
  18. 18Snyder, P.J., Bhasin, S., Cunningham, G.R., et al. (2016). Effects of testosterone treatment in older men. New England Journal of Medicine, 374(7), 611–624. DOI: 10.1056/NEJMoa1506119
  19. 19Lincoff, A.M., Bhasin, S., Flevaris, P., et al. (2023). Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine, 389(2), 107–117. DOI: 10.1056/NEJMoa2215025
  20. 20Huang, G., Travison, T.G., Bhattacharya, R., et al. (2024). Testosterone treatment and fractures in men with hypogonadism. New England Journal of Medicine, 390(3), 203–211. DOI: 10.1056/NEJMoa2308836
  21. 21Resnick, S.M., Matsumoto, A.M., Stephens-Shields, A.J., et al. (2017). Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment. JAMA, 317(7), 717–727. DOI: 10.1001/jama.2016.21044
  22. 22McBride, J.A., Carson, C.C., & Coward, R.M. (2019). Effects of testosterone supplementation on separate cognitive domains in cognitively healthy older men: a meta-analysis. Journal of the Endocrine Society, 3(8), 1465–1481. DOI: 10.1210/js.2019-00122
  23. 23Walther, A., Breidenstein, J., & Miller, R. (2019). Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry, 76(1), 31–40. DOI: 10.1001/jamapsychiatry.2018.2734
  24. 24Araujo, A.B., Dixon, J.M., Suarez, E.A., Murad, M.H., Guey, L.T., & Wittert, G.A. (2011). Endogenous testosterone and mortality in men: a systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism, 96(10), 3007–3019. DOI: 10.1210/jc.2011-1137
  25. 25Laughlin, G.A., Barrett-Connor, E., & Bergstrom, J. (2008). Low serum testosterone and mortality in older men. Journal of Clinical Endocrinology & Metabolism, 93(1), 68–75. DOI: 10.1210/jc.2007-1792
  26. 26Kupelian, V., Page, S.T., Araujo, A.B., et al. (2008). Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency associated with development of metabolic syndrome in nonobese men. Journal of Clinical Endocrinology & Metabolism, 93(4), 1497–1503. DOI: 10.1210/jc.2007-1457
  27. 27Kupelian, V., Hayes, F.J., Link, C.L., Rosen, R., & McKinlay, J.B. (2008). Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. Journal of Clinical Endocrinology & Metabolism, 93(9), 3403–3410. DOI: 10.1210/jc.2008-0054
  28. 28Marriott, R.J., Murray, K., Hankey, G.J., Dwivedi, G., & Yeap, B.B. (2022). Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: the UK Biobank prospective cohort study. Alzheimer's & Dementia, 18(10), 1907–1918. DOI: 10.1002/alz.12529
  29. 29Zhang, Z., Kang, D., & Li, H. (2021). Testosterone and cognitive impairment or dementia in middle-aged or aging males: causation and intervention. Journal of Geriatric Psychiatry and Neurology, 34(6), 564–577. DOI: 10.1177/0891988720933351
  30. 30Zitzmann, M. (2020). Testosterone, mood, behaviour and quality of life. Andrology, 8(6), 1598–1605. DOI: 10.1111/andr.12867
  31. 31Shores, M.M., Matsumoto, A.M., Sloan, K.L., & Kivlahan, D.R. (2006). Low serum testosterone and mortality in male veterans. Archives of Internal Medicine, 166(15), 1660–1665. DOI: 10.1001/archinte.166.15.1660
  32. 32Rao, P.M., Kelly, D.M., & Jones, T.H. (2013). Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature Reviews Endocrinology, 9(8), 479–493. DOI: 10.1038/nrendo.2013.122
  33. 33Phthalates and sex steroid hormones among men from NHANES, 2013–2016. (2020). Journal of Clinical Endocrinology & Metabolism, 105(3), dgaa189. DOI: 10.1210/clinem/dgaa189
  34. 34Leproult, R., & Van Cauter, E. (2011). Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA, 305(21), 2173–2174. DOI: 10.1001/jama.2011.710
  35. 35Smith, S.J., Lopresti, A.L., Teo, S.Y.M., & Fairchild, T.J. (2022). Effects of exercise training on resting testosterone concentrations in insufficiently active men: a systematic review and meta-analysis. Sports Medicine, 52(5), 1113–1128. DOI: 10.1007/s40279-021-01635-2
  36. 36Hsiao, P.C., et al. (2024). The effects of aerobic exercise training on testosterone concentration in individuals who are obese or have type 2 diabetes: a systematic review and meta-analysis. Sports Medicine, Open, 10(1), 114. DOI: 10.1186/s40798-024-00781-x
  37. 37Caliber, M.D., & Hackett, G. (2021). Testosterone replacement therapy added to intensive lifestyle intervention in older men with obesity and hypogonadism. Journal of Clinical Endocrinology & Metabolism, 106(3), e1096–e1110. DOI: 10.1210/clinem/dgaa716
  38. 38Prasad, A.S., Mantzoros, C.S., Beck, F.W.J., Hess, J.W., & Brewer, G.J. (1996). Zinc status and serum testosterone levels of healthy adults. Nutrition, 12(5), 344–348. DOI: 10.1016/s0899-9007(96)80058-x
  39. 39Corona, G., Rastrelli, G., Monami, M., et al. (2013). Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology, 168(6), 829–843. DOI: 10.1530/EJE-12-0955
  40. 40Endocrine Society. (2018). Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. DOI: 10.1210/jc.2018-00229
  41. 41Mulhall, J.P., Trost, L.W., Brannigan, R.E., et al. (2018). Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology, 200(2), 423–432. DOI: 10.1016/j.juro.2018.03.115
  42. 42Travison, T.G., Vesper, H.W., Orwoll, E., et al. (2017). Harmonized reference ranges for circulating testosterone levels in men of four cohort studies. Journal of Clinical Endocrinology & Metabolism, 102(4), 1161–1173. DOI: 10.1210/jc.2016-2935
  43. 43Mehta, P.H., & Josephs, R.A. (2010). Testosterone and cortisol jointly regulate dominance: evidence for a dual-hormone hypothesis. Hormones and Behavior, 58(5), 898–906. DOI: 10.1016/j.yhbeh.2010.08.020
  44. 44Mazur, A., & Booth, A. (1998). Testosterone and dominance in men. Behavioral and Brain Sciences, 21(3), 353–363. DOI: 10.1017/S0140525X98001228
  45. 45Bhasin, S., & Snyder, P.J. (2025). Testosterone treatment in middle-aged and older men with hypogonadism. New England Journal of Medicine, 393(6), 581–591. DOI: 10.1056/NEJMra2404637
  46. 46Andersen, M.L., Alvarenga, T.F., Mazaro-Costa, R., Hachul, H.C., & Tufik, S. (2011). The association of testosterone, sleep, and sexual function in men and women. Brain Research, 1416, 80–104. DOI: 10.1016/j.brainres.2011.07.060
  47. 47Ma, H., Liang, X., Li, S., Ma, X., & Wang, Y. (2020). The effects of testosterone on bone health in males with testosterone deficiency. BMC Endocrine Disorders, 20, 52. DOI: 10.1186/s12902-020-0509-6
  48. 48Snyder, P.J., Kopperdahl, D.L., Stephens-Shields, A.J., et al. (2017). Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone. JAMA Internal Medicine, 177(4), 471–479. DOI: 10.1001/jamainternmed.2016.9539
  49. 49Basaria, S., Coviello, A.D., Travison, T.G., et al. (2010). Adverse events associated with testosterone administration. New England Journal of Medicine, 363(2), 109–122. DOI: 10.1056/NEJMoa1000485
  50. 50Shores, M.M., Moceri, V.M., Gruber, S.A., et al. (2004). Low testosterone is associated with decreased function and increased mortality risk. Journal of the American Geriatrics Society, 52(12), 2077–2081. DOI: 10.1111/j.1532-5415.2004.52561.x
  51. 51Zarrouf, F.A., Artz, S., Griffith, J., Sirbu, C., & Kommor, M. (2009). Testosterone and depression: systematic review and meta-analysis. Journal of Psychiatric Practice, 15(4), 289–305. DOI: 10.1097/01.pra.0000358315.88931.fc
  52. 52Rosner, W., Auchus, R.J., Azziz, R., Sluss, P.M., & Raff, H. (2007). Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. Journal of Clinical Endocrinology & Metabolism, 92(2), 405–413. DOI: 10.1210/jc.2006-1864
  53. 53Walker, M. (2017). Why We Sleep: Unlocking the Power of Sleep and Dreams. Scribner.
  54. 54Sapolsky, R.M. (2004). Why Zebras Don't Get Ulcers (3rd ed.). Henry Holt. --- ## METADATA ### Word Count Targets | Block | Target | Actual | |-------|--------|--------| | Masthead | 50–100 | 78 | | Key Findings | 150–250 | 230 | | Opening | 600–900 | 870 | | Mechanism | 1,500–2,500 | 1,820 | | Evidence | 1,200–1,800 | 1,560 | | Stakes | 500–800 | 680 | | Protocol | 500–800 | 720 | | Verdict | 400–700 | 640 | | *TOTAL | 4,900–7,850 | ~5,870 | ### Stat Collision Check | Stat | Appears in blocks | Varied framing? | |------|-------------------|-----------------| | ~17% decline | Key Findings, Opening, Stakes | Yes, headline stat → contextual → environmental | | 10–15% sleep reduction | Key Findings, Evidence (Study #4), Protocol | Yes, headline → study result → intervention rationale | | +7.9 kg fat-free mass | Key Findings, Evidence (Study #1) | Yes, headline → detailed study context | | RR 1.35 mortality | Key Findings, Evidence (Study #5), Stakes, Verdict | Yes, headline → study result → consequence → caveat with MR | | ~2% free testosterone | Mechanism (Big Stat), Mechanism prose | Yes, stat display → clinical implication | ### dfn Terms per Block | Block | Count | Terms | |-------|-------|-------| | Opening | 8 | dose-response, meta-analyses, muscle protein synthesis, glucose metabolism, erythropoiesis, hypothalamic-pituitary-gonadal axis, secular decline, biochemical hypogonadism | | Mechanism | 27 | hypothalamus, gonadotropin-releasing hormone, anterior pituitary, luteinising hormone, Leydig cells, cAMP-PKA cascade, steroidogenesis, CYP11A1, HSD3B, HSD17B3, sex hormone-binding globulin, albumin, free testosterone, androgen receptor, β-catenin, follistatin, myogenesis, dihydrotestosterone, 5α-reductase, non-genomic signalling, ventral tegmental area, nucleus accumbens, prefrontal cortex, dopaminergic, aromatase, estradiol, liquid chromatography-mass spectrometry, dual-hormone hypothesis | | Evidence | 2 | causal inference, Mendelian randomization | | Stakes | 2 | sarcopenia, endocrine-disrupting chemicals, phthalates | | Protocol | 2 | slow-wave sleep, hypogonadotropic hypogonadism | | Verdict | 0 | (references terms already introduced) | | TOTAL | 43 |, | ### Internal Links | Target | Clean URL | Used in block | |--------|-----------|---------------| | Cortisol SDD | /bio/hormones/cortisol-science/ |, (available for Coder Nav Rail) | | Hormones Guide | /bio/hormones/optimization-drive-vitality/ |, (available for Coder Nav Rail) | | Melatonin SDD | /bio/sleep/melatonin-science/ |, (available for Coder Nav Rail) | ### Editorial Pause Inventory | Block | Pause count | Labels used | |-------|-------------|-------------| | Opening | 3 | Editorial pause, Editorial pause, Section verdict | | Mechanism | 4 | Editorial pause ×4 | | Evidence | 3 | Editorial pause, Editorial pause, Section verdict | | Stakes | 1 | Editorial pause | | Protocol | 1 | Editorial pause | | Verdict | 1 | Final line | | TOTAL | 13* | | ### Pull Quote Inventory | Block | Quote text | Attribution | Word count | |-------|-----------|-------------|------------| | Mechanism | "The axis does not need stimulation. It needs the noise removed." | Editorial synthesis of HPG axis research | 12 | | Evidence | "Testosterone is not a volume dial. It is a feedback-controlled signalling system, and the signal quality matters more than the signal strength." | Editorial synthesis | 24 |
No references match your search.

DOI links resolve to the original publisher via doi.org. Open-access versions can often be found via Google Scholar.

High-Performance Insights

Leave a Reply

Your email address will not be published. Required fields are marked *